Akari Therapeutics (AKTX) jumped over 241.8% on Friday. The upside came after the company released promising new preclinical data for its lead cancer drug, AKTX-101, and announced a $5.5 million private placement that strengthens its balance sheet.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Breakthrough Data for AKTX‑101
Early tests showed that AKTX-101 strongly slowed tumor growth in lab models. The therapy targets the C5a/C5aR pathway, a key driver of tumor growth and the immune system. The new data also suggests it may help the body’s immune cells fight cancer again.
Investors see the new data as a possible turning point for the small biotech, which has been trying to grow beyond rare-disease drugs and move into cancer treatments. The results are still early, but they give Akari a clearer path to push AKTX-101 toward human trials.
$5.5 Million Private Placement Adds Fuel
Alongside the data release, Akari disclosed a $5.5 million private placement with institutional investors. The funding provides fresh capital to support ongoing research and prepare for future clinical work.
The company said the new funding will help speed up the work of AKTX-101 and support its R&D efforts. For a small company like Akari, the extra cash matters a lot, especially as it moves into the costly stages of clinical testing.
The combination of strong data and fresh funding has lifted hopes for Akari’s drug pipeline. If AKTX-101 keeps showing good results, it could help the company land partners or make a bigger push into cancer drugs. For now, investors are betting that Akari’s early progress is the start of a new, more ambitious growth phase.
What Is the Price Target for AKTX?
Turning to Wall Street, AKTX stock has a Moderate Buy consensus rating based on one Buy and one Hold assigned in the last three months. At $27.00, the average Akari stock price target implies a 116% upside potential.
